Endothelial dysfunction in chronic heart failure: Some new basic mechanisms

Italian Heart Journal

Volumn 1, Issue 10, 2000, Pages 656-661

  Bachetti, T ^a  

^a IRCCS   (Italy)

Author keywords

Apoptosis; Endothelin; Nitric oxide; Nitric oxide synthase; Remodeling

Indexed keywords

ENDOTHELIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

APOPTOSIS; BLOOD CELL; BLOOD FLOW; BLOOD VESSEL COMPLIANCE; CELL ADHESION; CELL DAMAGE; CHRONIC DISEASE; ENDOTHELIUM INJURY; ENZYME ACTIVITY; HEART FAILURE; HUMAN; PATHOGENESIS; PROTEIN SYNTHESIS; REVIEW; VASOCONSTRICTION; VASODILATATION;

ANIMALS; APOPTOSIS; CELL ADHESION; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HUMANS; NITRIC OXIDE; RATS; VASOCONSTRICTION; VASODILATION;

EID: 0033751388     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Strategie terapeutiche nel trattamento della disfunzione endoteliale: Fatti e prospettive
2. Endothelium as a therapeutic target in heart failure
3. Modulation of vascular endothelial gene expression by physical training in patients with chronic heart failure
4. Endothelium dependent vasodilation is attenuated in patients with heart failure
5. Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: Role of endothelium-derived nitric oxide
6. Effects of nitric oxide inhibition on basal forearm blood flow in patients with non-ischemic chronic heart failure
7. Relation between impairment in nitric oxide pathway and clinical status in patients with congestive heart failure
8. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure
9. Impaired acetyl-choline-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors
10. Endothelium-dependent forearm vasodilation to acetylcholine but not to substance P is impaired in patients with heart failure
11. Endothelial function in chronic congestive heart failure
12. A comparison of regional blood flow and oxygen utilization during dynamic forearm exercise in normal subjects and in patients with congestive heart failure
13. Aorta and skeletal muscle NO-synthase expression in experimental heart failure
14. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure
15. Exercise improves flow-mediated vasodilation of skeletal muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress
16. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure
17. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic. Role of tumor necrosis factor-α
18. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase
19. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half life
20. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure
21. Correction of endothelial dysfunction in chronic heart failure: Additional effects of exercise training and oral L-arginine supplementation
22. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the 'arginine paradox'
23. Inflammatory molecules induce arginase activity in human endothelial cells
24. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease
25. Oxygen free radicals and congestive heart failure
26. Increased malondialdehyde in peripheral blood of patients with congestive heart failure
27. Increased oxidative stress in patients with congestive heart failure
28. Oxidative stress is related to exercise intolerance in patients with heart failure
29. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure
30. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: Role of enhanced vascular superoxide production
31. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training
32. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart
33. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle
34. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy
35. Inducible nitric oxide synthase (iNOS) in the human heart: Expression and localization in congestive heart failure
36. 2+ channels
37. Endothelin in human congestive heart failure
38. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
39. Plasma endothelin in chronic heart failure
40. Physiological significance of endothelin. Its role in congestive heart failure
41. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function
42. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
43. Fluid flow decreases preproendothelin mRNA levels and suppresses endothelin-1 peptide release in cultured human endothelial cells
44. Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
45. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo
46. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats
47. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
48. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors
49. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
50. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
51. The endothelium as a regulator of vascular smooth muscle proliferation
52. Growth factor activity of endothelin on vascular smooth muscle
53. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling
54. Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure
55. Loss of intermediate-sized coronary arteries and capillary proliferation after left ventricular failure in rats
56. Impaired endothelium-mediated vasodilation is not the principal cause of vasoconstriction in heart failure
57. Ultra-structural changes of blood capillaries in patients with microvascular angina, hypertrophic cardiomyopathy, and dilated cardiomyopathy
58. Small vessel disease (SVD) in patients with unexplained ventricular arrhythmia and dilated congestive cardiomyopathy
59. Evaluation of skeletal muscle capillary basement membrane thickness in congestive heart failure
60. Ultrastructural analysis of skeletal muscle. Microvascular dimensions and basement membrane thickness in chronic heart failure
61. Evidence of increased microvascular resistance and arteriolar hyalinosis in skin in congestive heart failure secondary to idiopathic dilated cardiomyopathy
62. Capillary density of skeletal muscle: A contributing mechanism for exercise intolerance in class II-III chronic heart failure independent of other peripheral alterations
63. Effects of orthotopic cardiac transplantation on structural microangiopathy and abnormal hemodynamics in idiopathic dilated cardiomyopathy
64. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion
65. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation
66. Up-regulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure
67. Chronic congestive heart failure is associated with a phenotype shift of intramyocardial endothelial cells
68. Expression of cell adhesion molecules in dilated cardiomyopathy. Evidence for endothelial activation in inflammatory cardiomyopathy
69. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
70. Expression of adhesion molecules is specific and time-dependent in cytokine-stimulated endothelial cells in culture
71. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure
72. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure
73. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation
74. Plasticity of the pathologic heart
75. New targets for heart-failure therapy: Endothelin, inflammatory cytokines, and oxidative stress
76. Endotoxin and immune activation in chronic heart failure: A prospective cohort study
77. Synergistic effect of tumor necrosis factor-α on anoxia-reoxygenation-mediated apoptosis in cultured human coronary endothelial cells
78. 1 receptor and PKC activation
79. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: Modulation of Fas/Fas ligand and caspase-3 pathway
80. Direct effects of endotoxin on the endothelium: Barrier function and injury
81. Nitric oxide inhibits stress-induced endothelial cell apoptosis
82. Apoptosis of skeletal muscle myofibers and interstitial cells in experimental heart failure